Royalty Pharma PLC $RPRX Shares Purchased by World Investment Advisors

World Investment Advisors grew its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 21.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 58,434 shares of the biopharmaceutical company’s stock after buying an additional 10,178 shares during the quarter. World Investment Advisors’ holdings in Royalty Pharma were worth $2,258,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in RPRX. LM Advisors LLC acquired a new position in shares of Royalty Pharma during the fourth quarter worth about $26,000. Lloyd Advisory Services LLC. purchased a new position in Royalty Pharma during the 4th quarter valued at about $30,000. Smartleaf Asset Management LLC raised its position in Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares during the last quarter. Private Trust Co. NA lifted its holdings in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 288 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its holdings in shares of Royalty Pharma by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 446 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Marshall Urist sold 13,684 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $52.75, for a total value of $721,831.00. Following the transaction, the executive vice president directly owned 18,197 shares in the company, valued at $959,891.75. This trade represents a 42.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the sale, the director owned 191,803 shares of the company’s stock, valued at $10,165,559. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 199,185 shares of company stock worth $10,082,926 over the last three months. 18.84% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. UBS Group upped their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Citigroup increased their target price on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Morgan Stanley boosted their price target on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Finally, JPMorgan Chase & Co. upped their price objective on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average target price of $53.71.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $52.96 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The firm has a market cap of $30.50 billion, a PE ratio of 36.03, a P/E/G ratio of 1.46 and a beta of 0.43. The firm has a 50 day simple moving average of $52.17 and a 200-day simple moving average of $46.06. Royalty Pharma PLC has a 1-year low of $34.08 and a 1-year high of $56.50.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The firm had revenue of $630.58 million during the quarter, compared to analysts’ expectations of $881.69 million. On average, equities analysts expect that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were issued a $0.235 dividend. The ex-dividend date was Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.